Medi-Physics' Ceretec imaging agent launching in mid-June for detecting infections.
This article was originally published in The Gray Sheet
MEDI-PHYSICS' CERETEC NEW FORMULATION WILL BE LAUNCHED at the Society of Nuclear Medicine's annual meeting June 12-15 in Minneapolis. Three improvements of the diagnostic imaging agent Ceretec (technetium Tc99m exametazime) were approved April 7 through two efficacy supplements.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.